TSC2 and cancer: Since all LAM lesions revealed ID1 positivity and compounds are available that target the expression or stability of this factor in cancer cells (apigenin, C527, and cannabidiol) [56–59], we next sought to evaluate the selective effect of these compounds in Tsc2-deficient cells; particularly in MEFs because this setting revealed a better dose-response relationship for everolimus (Fig 6C).